FGC
ENTA icon

Financial Gravity Companies’s Enanta Pharmaceuticals ENTA Stock Holding History

Financial Gravity Companies’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$4K Buy
+51
New +$3.91K ﹤0.01% 759
2018
Q1 		$13K Sell
132
-1,999
-94% -$154K 0.01% 548
2017
Q4 		$181K Buy
+2,131
New +$107K 0.21% 93

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Financial Gravity Companies's ENTA Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Enanta Pharmaceuticals (ENTA) in Q4 2018: 51 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #759 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in ENTA as recently as Q1 2018.

Financial Gravity Companies first reported a position in ENTA in Q4 2017 and has held it in 3 quarters since. The position peaked at $181K in Q4 2017. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

  • Financial Gravity Companies held 51 shares of Enanta Pharmaceuticals worth $4K as of Q4 2018.
  • Enanta Pharmaceuticals was a new Financial Gravity Companies position in Q4 2018.
  • Enanta Pharmaceuticals made up ﹤0.01% of Financial Gravity Companies's portfolio in Q4 2018, its #759 holding.
  • Financial Gravity Companies first reported a position in Enanta Pharmaceuticals in Q4 2017 and has held it in 3 quarters since.
  • Financial Gravity Companies's Enanta Pharmaceuticals position peaked at $181K in Q4 2017.
  • 183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.